Gene Mapping Ability Will Further Validate GeneLink's DNA Banking Service
April 11, 2000

MARGATE, N.J., Apr 11, 2000 (BW HealthWire) -- GeneLink BioSciences, Inc. (OTC BB:GNLK), is extremely excited about recent news involving the mapping of the human genetic blueprint. This ability will eventually enable scientists to dissect DNA strands and completely decode all the elements that make up the human genetic pattern. Celera Genomics (NYSE:CRA) recently announced making this enormous scientific leap, having completed the total separation of human DNA into all of it's separate genes. 

GeneLink is the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. GeneLink's business model involves DNA banking, the collection and long-term storage of an individual's DNA inexpensively, while that individual is living or shortly after death. The necessity to save individual DNA "data" will be fully recognized in the very near future, with GeneLink's DNA banking ability playing a major role in the field of human genomics. "With these recent discoveries in human DNA mapping, companies like Celera will be able to offer something like a "human road map' and GeneLink will play the role of the storage facility," GeneLink CEO John R. DePhillipo commented.

GeneLink BioSciences, Inc. is a fully reporting company, trading on the OTC Bulletin Board. The company's DNA banking service creates a genetic history that enables families to determine if they are at risk for certain inherited diseases. GeneLink's patent pending DNA Collection Kit' utilizes a noninvasive process for collecting saliva. The DNA is then extracted and stored for up to 75 years at the University of North Texas Health Science Center at Fort Worth, Texas, a 105 year old medical facility. The company believes that its 75 year storage program is the longest term being offered in the country to date.

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE: GeneLink BioSciences, Inc.